Yousef Al-Abed Selected Research

saquinavir-NO

10/2012	Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.
8/2012	Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells.
3/2012	Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.
7/2011	Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells.
2/2011	In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells.
12/2010	Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.
5/2009	The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yousef Al-Abed Research Topics

Disease

43	Inflammation (Inflammations) 01/2022 - 01/2003
24	Sepsis (Septicemia) 01/2022 - 11/2004
19	Neoplasms (Cancer) 01/2022 - 10/2007
9	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 07/2005
9	Infections 01/2021 - 09/2002
8	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 07/2008
7	Endotoxemia 01/2019 - 03/2006
6	Melanoma (Melanoma, Malignant) 10/2019 - 09/2008
5	Neuroinflammatory Diseases 01/2020 - 01/2011
4	Ischemia 01/2021 - 04/2002
4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2018 - 06/2011
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2016 - 07/2005
4	Arthritis (Polyarthritis) 06/2015 - 01/2002
3	Chronic Disease (Chronic Diseases) 01/2022 - 12/2015
3	Hyperglycemia 10/2016 - 07/2005
3	Neoplasm Metastasis (Metastasis) 01/2015 - 01/2009
3	Necrosis 03/2012 - 04/2002
3	Amyloid Plaque 02/2012 - 07/2008
3	Pneumonia (Pneumonitis) 01/2011 - 10/2005
2	Anemia 01/2022 - 01/2020
2	Fibrosis (Cirrhosis) 12/2021 - 09/2010
2	Disease Progression 01/2020 - 01/2011
2	Glioblastoma (Glioblastoma Multiforme) 09/2018 - 01/2014
2	Multiple Sclerosis 01/2018 - 12/2016
2	Hyperplasia 01/2017 - 09/2010
2	Acute Kidney Injury (Acute Renal Failure) 01/2017 - 01/2012
2	Carotid Artery Injuries 01/2017 - 12/2015
2	Rheumatoid Arthritis 12/2016 - 01/2011
2	Pulmonary Hypertension 12/2016 - 03/2012
2	Colitis 12/2014 - 01/2014
2	Colonic Neoplasms (Colon Cancer) 10/2014 - 10/2012
2	Asthma (Bronchial Asthma) 02/2014 - 09/2010
2	Carcinogenesis 08/2012 - 01/2009
2	Prostatic Neoplasms (Prostate Cancer) 03/2012 - 02/2011
2	Endometriosis 01/2012 - 07/2009
2	Brain Ischemia (Cerebral Ischemia) 03/2011 - 04/2002
2	Experimental Melanoma 12/2010 - 05/2009

Drug/Important Bio-Agent (IBA)

28	CytokinesIBA 01/2021 - 01/2002
25	Macrophage Migration-Inhibitory FactorsIBA 01/2018 - 01/2002
19	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2002
18	HMGB1 Protein (HMG1)IBA 01/2022 - 11/2004
11	Pharmaceutical PreparationsIBA 01/2019 - 08/2010
9	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2019 - 09/2008
7	Saquinavir (Invirase)FDA Link 12/2015 - 05/2009
7	saquinavir-NOIBA 10/2012 - 05/2009
6	AntibodiesIBA 11/2019 - 11/2005
6	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2017 - 09/2008
6	semapimodIBA 12/2016 - 07/2008
5	Peptides (Polypeptides)IBA 01/2020 - 07/2008
5	HIV Protease InhibitorsIBA 10/2019 - 05/2009
4	LipopolysaccharidesIBA 11/2019 - 01/2012
4	Cholinergic Agents (Cholinergics)IBA 01/2019 - 04/2005
4	3-(2,4-dimethoxybenzylidene)anabaseineIBA 01/2017 - 04/2007
4	Amyloid (Amyloid Fibrils)IBA 04/2015 - 07/2008
4	alpha7 Nicotinic Acetylcholine ReceptorIBA 08/2010 - 01/2003
3	LipidsIBA 12/2021 - 10/2007
3	Small Interfering RNA (siRNA)IBA 12/2021 - 10/2007
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 04/2007
3	Antiviral Agents (Antivirals)IBA 12/2019 - 09/2011
3	Lopinavir FDA Link 10/2019 - 11/2015
3	DisulfidesIBA 01/2019 - 03/2012
3	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 06/2011
3	AutoantibodiesIBA 10/2016 - 04/2011
3	Streptozocin (Streptozotocin)FDA Link 10/2016 - 03/2007
3	EndotoxinsIBA 01/2014 - 04/2007
3	Protease Inhibitors (Protease Inhibitor)IBA 08/2012 - 02/2011
3	Messenger RNA (mRNA)IBA 03/2012 - 09/2010
3	EnzymesIBA 09/2011 - 04/2002
3	Nicotine FDA Link 11/2007 - 11/2004
2	ElementsIBA 12/2021 - 12/2019
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 03/2011
2	Interferon-gamma (Interferon, gamma)IBA 01/2021 - 03/2007
2	CXC ChemokinesIBA 01/2021 - 10/2005
2	PeptidomimeticsIBA 01/2020 - 10/2017
2	ChemokinesIBA 01/2020 - 09/2002
2	Cholinergic AgonistsIBA 11/2019 - 11/2004
2	CaspasesIBA 11/2019 - 04/2010
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2019 - 01/2017
2	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2019 - 01/2009
2	Galantamine (Galanthamine)FDA LinkGeneric 01/2019 - 01/2009
2	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2019 - 11/2004
2	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2018 - 01/2015
2	anti-dsDNA autoantibodyIBA 10/2017 - 06/2011
2	Adenosine Triphosphate (ATP)IBA 01/2017 - 12/2010
2	Nuclear Antigens (Extractable Nuclear Antigens)IBA 10/2016 - 06/2011
2	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2016 - 06/2010
2	Toll-Like Receptor 4IBA 12/2015 - 12/2015
2	Dextran SulfateIBA 12/2014 - 01/2014
2	Antineoplastic Agents (Antineoplastics)IBA 08/2012 - 08/2009
2	Nicotinic AgonistsIBA 01/2012 - 11/2004
2	Amyloid beta-PeptidesIBA 04/2011 - 07/2008
2	InterleukinsIBA 03/2011 - 03/2007
2	AcetylcholinesteraseIBA 03/2011 - 01/2009
2	CollagenIBA 03/2011 - 09/2010
2	methyl acetateIBA 09/2010 - 07/2005

Therapy/Procedure

10	Therapeutics 12/2021 - 01/2009
5	Vagus Nerve Stimulation 03/2022 - 01/2018
5	Ligation 01/2020 - 11/2005
5	Punctures 01/2020 - 11/2005
3	Drug Therapy (Chemotherapy) 01/2017 - 05/2009